Mereo BioPharma Group plc (MREO) Stock Score, Valuation & Financial Research
Mereo BioPharma Group plc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 16/100.
Quick answer for MREO
Mereo BioPharma Group plc currently has a Wall Street Score of 16/100. The stored market price is $0.27. Its financial score is 24/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Mereo BioPharma Group plc does
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS
MREO financial snapshot
- Wall Street Score:
- 16/100
- Current price:
- $0.27
- Market capitalization:
- $42.5M
- Revenue:
- $500K
- Net income:
- $-35.7M
- Free cash flow:
- $-31.0M
- Cash:
- $36.2M
- Total debt:
- $202K
- EPS:
- -0.26
- Financial score:
- 24/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-31.0M, showing cash burn in the current stored period.
- The balance sheet shows $36.2M of cash versus $202K of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 24/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research MREO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.